Abstract:Background: Uveal melanoma (UM) is the most common primary intraocular tumor in adults with a high incidence of metastasis. Standard care therapies for UM include enuclea-tion and radiation, which are minimally effective in prolonging patient survival. Oncolytic virus treatment has become a new trend in cancer field. Of which, oncolytic herpes simplex virus type 1 (HSV-1) therapy is one of the most effective antitumor treatments. Here, we established an oncolytic HSV-1 encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), tested its efficacy in UM therapy, and investigated the innate immune response induced by this virus. Methods: Oncolytic HSV-1 expressing GM-CSF (HSV-GM-CSF) was constructed, then verified using qPCR and Western blot assays. Cell viability assays and transmission electron microscopy were conducted on three UM cell lines, MUM2B, 92.1, and MP41, to assess the cell-killing ability and virus infection of this virus. For in vivo experiments, BALB/c-nude mice in situ UM xenografts were established to testify the efficacy of the oncolytic virus, oncolytic HSV-1, and HSV-GM-CSF groups, respectively. IVIS images, ocular volumes, mice weights, and survivals were tracked to see the efficacy of the virus. Hematoxylin and eosin staining, immunohistochemistry, and flow cytometry analyses were conducted to demonstrate the immune activity after virus treatment. Results: All three tested UM cell lines were sensitive to infection by HSV-GM-CSF. In vivo xenograft experiments revealed that oncolytic virus HSV-1 reduced UM tumor volume and that oncolytic virus HSV-1 armed with GM-CSF enhanced the antitumor effect compared with unmodified HSV-1. The bodyweights of untreated control group mice were significantly lower than those of mice in either virus-treated group (HSV-1 or HSV-GM-CSF). Follow-up survivals were prolonged in the virus-treated groups compared with the control group and were prolonged to a greater extent in the HSV-GM-CSF group than in the HSV-1 group. Macrophage stimulation was observed following HSV-GM-CSF treatment. Conclusion: Our results indicate that the recombinant oncolytic virus HSV-GM-CSF is a potential therapeutic treatment for UM.

In Vitro and in Vivo Anti-Uveal Melanoma Activity of JSL-1, a Novel HDAC Inhibitor

The BET inhibitor JQ1 suppresses tumor survival by ABCB5-mediated autophagy in uveal melanoma

Abstract 4581: Identifying class 1 HDACs as a vulnerability for aggressive uveal melanoma

Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft

The Multi-Kinase Inhibitor Afatinib Serves As a Novel Candidate for the Treatment of Human Uveal Melanoma

Development of New Therapeutic Options for the Treatment of Uveal Melanoma

An Injectable Vitreous Substitute with Sustained Release of Metformin for Enhanced Uveal Melanoma Immunotherapy

Identification of targetable epigenetic vulnerabilities in uveal melanoma

Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma

Antitumor Efficacy of Oncolytic Herpes Virus Type 1 Armed with GM-CSF in Murine Uveal Melanoma Xenografts

Effects of Inhibition of Hedgehog Signaling on Cell Growth and Migration of Uveal Melanoma Cells.

Targeted Silencing Of Mart-1 Gene Expression By Rna Interference Enhances The Migration Ability Of Uveal Melanoma Cells

Study of Cinobufagin As a Promising Anticancer Agent in Uveal Melanoma Through Intrinsic Apoptosis Pathway

Evaluation of Pan-RAF Inhibitor LY3009120 on Human Uveal Melanoma Cell Line 92-1

BET Bromodomain Inhibition Potentiates Ocular Melanoma Therapy by Inducing Cell Cycle Arrest

Development and validation of immunogenic cell death-related signature for predicting the prognosis and immune landscape of uveal melanoma

Identifying biomarkers and novel therapeutic targets in uveal melanoma

A Long-Acting Curcumin Nanoparticle/In Situ Hydrogel Composite for the Treatment of Uveal Melanoma

Recent Advances and Challenges in Uveal Melanoma Immunotherapy

STAT6/LINC01637 axis regulates tumor growth via autophagy and pharmacological targeting STAT6 as a novel strategy for uveal melanoma

Uveal Melanoma: Progress in Molecular Biology and Therapeutics.